Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

1,000 publications—and counting

To date, over 1,000 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

ISPOR 2025
April 2025
Using regression discontinuity in time design for real-world comparative effectiveness: A case study for the second-line use of pembrolizumab in advanced non-small cell lung cancer
Chen N, Zemplenyi A, Adamson B, et al.
Blood Cancer Journal
April 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
Dong S, Banerjee R, Khan A M, et al.
ISPOR
April 2025
From data to decisions: the role of real-world evidence in recent multiple myeloma drug approvals in the US and EU
Chen A, Palladino L, Taylor L
ISPOR
April 2025
Leveraging machine learning to assess the association of rash and survival in patients with advanced NSCLC
Yuan Q, Dolor A, Qian Y, et al.
ISPOR
April 2025
Performance assessment and validation of real-world response data generated using a deep learning-based natural language processing model across multiple solid tumors
Magee K, Yuan Q, Blarre A, et al.
ISPOR
April 2025
Analytical approaches to estimate medication persistence from EHR data: a study of TKIs in patients with EGFR+ advanced NSCLC
Li X, Jarrett B, Kerr B, et al.
ISPOR
April 2025
Augmenting race and ethnicity in a real-world oncology cohort using the Bayesian improved surname geocoding methodology
Ho G, Mpofu P, Mbah O, et al.
ISPOR
April 2025
Advancing breast cancer research in Japan using EHR-derived real-world data
Adamson B, Ng D, Pittell H, et al.
ISPOR
April 2025
Patient characteristics and treatment patterns in extensive-stage small cell lung cancer (ES-SCLC)
Iams W, Miller T, Reiss S, et al.

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2025